Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pDB4697
(Plasmid #171125)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 171125 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    pEASY-blunt
  • Backbone manufacturer
    TransGen Biotech
  • Vector type
    Other

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin and Kanamycin, 100 & 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    ura4
  • Species
    S. pombe (fission yeast)
  • Mutation
    non applicable

Cloning Information

  • Cloning method Unknown

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pDB4697 was a gift from Li-Lin Du (Addgene plasmid # 171125 ; http://n2t.net/addgene:171125 ; RRID:Addgene_171125)
  • For your References section:

    An improved auxin-inducible degron system for fission yeast. Zhang XR, Zhao L, Suo F, Gao Y, Wu Q, Qi X, Du LL. G3 (Bethesda). 2022 Jan 4;12(1):jkab393. doi: 10.1093/g3journal/jkab393. 10.1093/g3journal/jkab393 PubMed 34849776